This suggests that inhibiting RIPK1 in tumour cells may induce autophagic defects, increase apoptotic sensitivity, and emerge as a novel strategy to overcome autophagy-dependent chemoresistance in cancer. This evidence concerns the gene RIPK1 and neoplasm.